Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings In Brief

This article was originally published in The Gray Sheet

Executive Summary

Cooper Companies: Firm's proposed $1.2 bil. acquisition of Ocular Sciences garners required shareholder approval Nov. 16. However, closure of the transaction, originally expected by November, continues to be delayed as the Federal Trade Commission reviews additional information it requested in September to supplement the two companies' initial Aug. 6 submission of merger-related information (1"The Gray Sheet" Sept. 13, 2004, p. 24). Cooper now predicts the transaction will close during the first half of its fiscal 2005, which began Nov. 1...

You may also be interested in...



AngioDynamics Aims To Leverage Endovenous Laser Reimbursement

AngioDynamics is developing "more aggressive" marketing efforts for its VenaCure laser ablation system on the heels of favorable Medicare reimbursement codes and rates for 2005

AngioDynamics Aims To Leverage Endovenous Laser Reimbursement

AngioDynamics is developing "more aggressive" marketing efforts for its VenaCure laser ablation system on the heels of favorable Medicare reimbursement codes and rates for 2005

Cooper/Ocular Sciences Merger Could Be Delayed By FTC Info Request

Cooper Companies' near-term sales projections could be impacted by personnel retention issues if a recent FTC information request delays the firm's pending acquisition of Ocular Sciences

Related Content

UsernamePublicRestriction

Register

MT021209

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel